Open Access iconOpen Access

ARTICLE

crossmark

Thymoquinone as a potential therapeutic for Alzheimer’s disease in transgenic Drosophila melanogaster model

NARAYANAN NAMPOOTHIRI V. P.1, VIGNESH SUNDARARAJAN1, PALLAVI DAN1, G. DEVANAND VENKATASUBBU2,*, SAHABUDEEN SHEIK MOHIDEEN1,*

1 Department of Biotechnology, School of Bioengineering, SRM Institute of Science and Technology, Kattankulathur, 603203, India
2 Department of Physics and Nanotechnology, School of Bioengineering, SRM Institute of Science and Technology, Kattankulathur, 603203, India

* Address correspondence to: G. Devanand Venkatsubbu, email; Sahabudeen Sheik Mohideen, email

BIOCELL 2021, 45(5), 1251-1262. https://doi.org/10.32604/biocell.2021.015090

Abstract

Alzheimer’s disease (AD) is one of the most common forms of dementia. Cognitive dysfunction and memory loss are the two main clinical symptoms of AD. Drosophila melanogaster models of AD, which are based on overexpression of human amyloid β (Aβ) or human tau (hTau) protein, have been used to study the mechanism underlying AD and to screen potential therapeutic compounds. Drugs that are currently available for AD provide only symptomatic relief. Huge unmet medical needs exists to slow, stop, or reverse the progression of AD. Thymoquinone (TQ) is an active ingredient isolated from Nigella sativa (NS) and possesses various pharmacological activities, and it is also a potential neuropharmacological agent. The current study was performed to investigate the effect of dietary administration of TQ at concentrations of 12.5 μM and 25 μM for 15 and 30 days on biochemical and behavioral parameters, gene, and protein expression of hTau, using Drosophila models of AD. Transgenic Drosophila models exhibiting pan-neuronal and eye-specific expression of hTau were generated using the GAL4/UAS system. Treatment with TQ at both concentrations resulted in a significant increase in behavioral activity, a significant reduction in the amount of reactive oxygen species (ROS), and restoration of depleted superoxide dismutase (SOD) and acetylcholine esterase (AChE) activities. A significant decrease in gene and protein expression of hTau was also observed at the molecular level for both concentrations of TQ. Therefore, TQ has the potential to be investigated as a potential therapeutic phytochemical for the treatment of AD in future studies.

Keywords


Cite This Article

APA Style
P., N.N.V., SUNDARARAJAN, V., DAN, P., VENKATASUBBU, G.D., MOHIDEEN, S.S. (2021). Thymoquinone as a potential therapeutic for alzheimer’s disease in transgenic <i>drosophila melanogaster</i> model. BIOCELL, 45(5), 1251-1262. https://doi.org/10.32604/biocell.2021.015090
Vancouver Style
P. NNV, SUNDARARAJAN V, DAN P, VENKATASUBBU GD, MOHIDEEN SS. Thymoquinone as a potential therapeutic for alzheimer’s disease in transgenic <i>drosophila melanogaster</i> model. BIOCELL . 2021;45(5):1251-1262 https://doi.org/10.32604/biocell.2021.015090
IEEE Style
N.N.V. P., V. SUNDARARAJAN, P. DAN, G.D. VENKATASUBBU, and S.S. MOHIDEEN "Thymoquinone as a potential therapeutic for Alzheimer’s disease in transgenic <i>Drosophila melanogaster</i> model," BIOCELL , vol. 45, no. 5, pp. 1251-1262. 2021. https://doi.org/10.32604/biocell.2021.015090

Citations




cc This work is licensed under a Creative Commons Attribution 4.0 International License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
  • 2698

    View

  • 1175

    Download

  • 0

    Like

Share Link